Why the study?
Extracellular vesicle microRNAs show promising potential as prognostic and diagnostic biomarkers and therapeutic targets in heart failure, warranting an updated summary of their pathophysiological roles and therapeutic applications.
Extracellular vesicle microRNAs show potential as prognostic and diagnostic biomarkers, as well as therapeutic targets, in heart failure.
Answers are grounded in this paper and cite their sources.
EV-miRNA cargo may mediate HF progression; leaves open biomarker or therapeutic targeting until prospective trials.
Extracellular vesicles (EVs) are emerging mediators of intracellular and inter-organ communications in cardiovascular diseases (CVDs), especially in the pathogenesis of heart failure through the transference of EV-containing bioactive substances. microRNAs (miRNAs) are contained in EV cargo and are involved in the progression of heart failure. Over the past several years, a growing body of evidence has suggested that the biogenesis of miRNAs and EVs are tightly regulated, and the sorting of miRNAs into EVs is highly selective and tightly controlled. Extracellular miRNAs, in particular circulating EV-miRNAs, have shown promising potential as prognostic and diagnostic biomarkers for heart failure and as therapeutic targets. In this review, we summarize the latest progress concerning the role of EV-miRNAs in HF and their application in a therapeutic strategy development for heart failure.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: